Adaptimmune Therapeutics plc

05/26/2022 | Press release | Distributed by Public on 05/27/2022 00:59

Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track